Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390793 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
A Phase 2 study of Acute Lymphoblastic Leukemia and Recurrent Acute Lymphoblastic Leukemia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 1
- Study location
NCT00390793 is a Phase 2 study of Acute Lymphoblastic Leukemia and Recurrent Acute Lymphoblastic Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 107 participants, below the 381-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00390793, a Phase 2 study of Acute Lymphoblastic Leukemia and Recurrent Acute Lymphoblastic Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well combination chemotherapy and dasatinib works in treating participants with Philadelphia-positive or B-cell receptor-ABL positive acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy in combination with dasatinib may work better in treating participants with Philadelphia-positive or BCR-ABL positive acute lymphoblastic leukemia.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Dexamethasone
- DRUG Cytarabine
- DRUG Dasatinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2006-09-28 |
| Est. Completion | 2024-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00390793
The ClinicalTrials.gov registry entry for NCT00390793 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 381-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (72% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00390793 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00390793 about?
NCT00390793 is a clinical study titled "Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.". This phase II trial studies how well combination chemotherapy and dasatinib works in treating participants with Philadelphia-positive or B-cell receptor-ABL positive acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrex...
What is the current status of trial NCT00390793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2006-09-28. Estimated completion is 2024-02-02.
What conditions does trial NCT00390793 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, BCR-ABL1 Fusion Protein Expression.
What interventions are being tested in trial NCT00390793?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Dexamethasone (DRUG), Cytarabine (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00390793?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390793 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RECRUITING · Phase 2
Explore more on PlainTrial
Acute Lymphoblastic Leukemia
All registered trials for this condition
Recurrent Acute Lymphoblastic Leukemia
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.